TB-500 for Injury Recovery: Protocol, Dosing, and What to Expect

What this protocol is for

TB-500 is the systemic companion to BPC-157 in serious injury recovery. Where BPC-157 favours local soft tissue and gut, TB-500 reaches further: muscle, ligament, the broader fascia network, the vascular layer that feeds the whole repair process. The mechanism runs through actin binding and cell migration. The molecule mobilises stem cells toward the injury, increases the population of cells available to lay down new tissue, and supports the vascular work that determines how fast the rebuild happens.

Anecdotally, users report TB-500 contributes most to the structural plateau phase of recovery, weeks four to eight, where the body has done the inflammatory work and is now remodeling. Research shows the thymosin beta-4 mechanism is well characterised in animal models; human-translatable clinical data is thinner than the popular framing suggests. Used by many in the recovery / biohacking space stacked with BPC-157 as the canonical recovery protocol, where the combined coverage outperforms either alone for non-trivial injuries.

This is a tactical, legal performance layer on top of the rehab work, not a substitute. The molecule has a long half-life (2 to 3 days), which simplifies dosing but also means timing errors compound over a cycle. Get the protocol right or expect underperformance.

Dose for injury recovery

Research protocols and user reports commonly cite 2 to 2.5 mg subcutaneous twice weekly. Some protocols use a loading phase: 5 mg total per week for the first 4 weeks, dropped to 2 to 2.5 mg per week for maintenance. Subcutaneous abdomen is the standard route; the long half-life means systemic exposure is consistent and local-site injection is less important than with BPC-157.

Cycle length

4–6 weeks loading at higher dose, then 4–8 weeks maintenance, depending on injury severity. Continuous use beyond 12 weeks has weak supporting evidence; cycling with a 2–4 week off-window is the conservative default.

Stack pairings

Commonly stacked with BPC-157.

Expected timeline

Week 1–2: minimal subjective change as the molecule loads into systemic exposure. Week 3–4: noticeable improvement in recovery between training, reduced soreness, faster bounce-back from rehab sessions. Week 5–8: structural plateau where the deeper tissue remodeling lands. The bigger functional gains land weeks 5 to 8 rather than the early phase.

Common mistakes

• Treating TB-500 like BPC-157 and dosing daily. The 2 to 3 day half-life means twice-weekly is the right rhythm. Daily dosing wastes molecule without proportional gain.
• Skipping the loading phase on serious injuries. The first 4 weeks at higher dose front-loads the cell-migration work that drives the rest of the cycle.
• Running TB-500 alone for soft tissue when BPC-157 is the better local match. Use the stack.
• Stopping at week 4 because nothing dramatic has happened. TB-500 gains land in the back half of the cycle, not the front.
• Cheap or improperly reconstituted product. Same rule as every peptide protocol: the vial is not where you save money.